Overview

Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0303）

Status:
Completed
Trial end date:
2017-01-06
Target enrollment:
Participant gender:
Summary
Evaluate the efficacy and safety of Anlotinib as the 3-line treatment of patients with advanced non-small lung cancer, with placebo control.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd